Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

60.50
+0.16000.27%
Volume:1.09M
Turnover:66.00M
Market Cap:11.71B
PE:403.33
High:61.75
Open:60.26
Low:60.21
Close:60.34
Loading ...

Incyte Corp - Phase 3 True-Pn1 Study Meets All Primary and Key Secondary Endpoints

THOMSON REUTERS
·
08 Mar

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients With Prurigo Nodularis (Pn) at 2025 American Academy of Dermatology Annual Meeting

THOMSON REUTERS
·
08 Mar

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Business Wire
·
08 Mar

Moody’s, Chubb, Incyte, Five9, CME: Insider Sales Surge

TIPRANKS
·
08 Mar

Incyte’s EVP Makes a Notable Stock Sale

TIPRANKS
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Teva Pharmaceutical (TEVA) and Incyte (INCY)

TIPRANKS
·
06 Mar

Incyte Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
04 Mar

EDSA: Raises $15 Million to Advance EB06…

Zacks Small Cap Research
·
03 Mar

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?

Insider Monkey
·
02 Mar

Incyte’s Top Executive Makes a Major Stock Move!

TIPRANKS
·
01 Mar

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Business Wire
·
28 Feb

High Growth Tech Stocks to Watch in US Market February 2025

Simply Wall St.
·
28 Feb

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
28 Feb

Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery

Insider Monkey
·
25 Feb

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
25 Feb

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
22 Feb